In a recap of the presentation made by Cempra at the JPMorgan Healthcare conference, JPMorgan analyst Jessica Fye noted that in the presentation and following breakout session, management said they are reluctant to run a multi-thousand patient safety study that would likely be required for approval of solithromycin for treatment of Community-Acquired Bacterial Pneumonia. However, the company announced the accelerated evaluation of soli into the ophthalmic antibiotic market and plans to meet with the FDA to discuss this potential, added Fye. She keeps a Neutral rating on Cempra shares, as she sees the company in a challenging position with CABP approval "appearing off the table."